Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 6/20 | 0.75 |
| ▸ | SLC5A2 | P31639 | 6/20 | 0.75 |
| ▸ | HPGD | P15428 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | GAA | P10253 | 4/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | ATM | Q13315 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.68 |
| ▸ | RELA | Q04206 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3408341 | 0.91 | LMNA (0.69) | SLC5A1SLC5A2HPGDMEN1KMT2A | |
| SCHEMBL3408972 | 0.89 | NFKB1 (0.61) | SLC5A1SLC5A2HPGDMEN1KMT2A | |
| SCHEMBL5622859 | 0.86 | NFKB1 (0.62) | SLC5A1SLC5A2HPGDMEN1KMT2A | |
| SCHEMBL457127 | 0.86 | SLC5A1 (1.00) | SLC5A1SLC5A2HPGDMEN1KMT2A | |
| SCHEMBL5623783 | 0.85 | NFKB1 (0.61) | SLC5A1SLC5A2HPGDMEN1KMT2A | |
| SCHEMBL5036945 | 0.83 | MAPT (0.77) | SLC5A1SLC5A2HPGDMEN1KMT2A | |
| SCHEMBL11628971 | 0.81 | SLC5A1 (0.71) | SLC5A1SLC5A2HPGDMEN1KMT2A | |
| Ononetin SCHEMBL2948430 | 0.81 | NPC1 (1.00) | SLC5A1SLC5A2HPGDMEN1KMT2A | |
| SCHEMBL1245802 | 0.81 | GAA (0.83) | SLC5A1SLC5A2HPGDMEN1KMT2A | |
| SCHEMBL3965268 | 0.81 | GAA (0.83) | SLC5A1SLC5A2HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005054169-A1 | PREPARATION METHOD OF 2-PHENYLACETOPHENONE DERIVATIVES | HANBUL COSMETIC CO., LTD. (KR) | 2005-06-16 | — | — | WO | claimed |
| US-20250084049-A1 | POLYCATIONIC SALTS OF PHENOLIC COMPOUNDS AND USES THEREOF | FIRMENICH INCORPORATED (US) | 2025-03-13 | — | — | US | disclosed |
| WO-2023278394-A1 | POLYCATIONIC SALTS OF PHENOLIC COMPOUNDS AND USES THEREOF | FIRMENICH INCORPORATED (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-3024489-B1 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND BETA-2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES | ALMIRALL SA (ES) | 2020-02-19 | — | — | EP | disclosed |
| EP-2961407-B1 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH 2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES | ALMIRALL SA (ES) | 2018-04-11 | — | — | EP | disclosed |
| WO-2017076990-A1 | ADDITION SALTS OF N-[4-(4-{[(1S)-1-(5-METHYL-4-OXO-3-PHENYL-3,4-DIHYDROPYRROLO[2,1-F][1,2,4]TRIAZIN-2-YL)ETHYL]AMINO}-7H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-1H-INDOL-6-YL]SULFAMIDE | ALMIRALL, S.A. (ES) | 2017-05-11 | — | — | WO | disclosed |
| US-9579316-B2 | Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscarinic receptor antagonist and β2 adrenergic receptor agonist activities | ALMIRALL, S.A. (ES) | 2017-02-28 | — | — | US | disclosed |
| US-9562039-B2 | Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities | ALMIRALL, S.A. (ES) | 2017-02-07 | — | — | US | disclosed |
| US-9388189-B2 | Pyrrolotriazinone derivatives as PI3K inhibitors | ALMIRALL, S.A. (ES) | 2016-07-12 | — | — | US | disclosed |
| US-20160166566-A1 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2016-06-16 | — | — | US | disclosed |
| EP-2146988-A1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | Almirall, S.A. (ES) | 2010-01-27 | — | — | EP | disclosed |
| WO-2009132774-A1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P39 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S. A. (ES) | 2009-11-05 | — | — | WO | disclosed |
| EP-2113503-A1 | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-11-04 | — | — | EP | disclosed |
| WO-2009124692-A1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | ALMIRALL, S.A. (ES) | 2009-10-15 | — | — | WO | disclosed |
| EP-2108641-A1 | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-10-14 | — | — | EP | disclosed |
| US-20090042891-A1 | Pyrazine Derivatives Useful as Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| WO-2008131922-A1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | WO | disclosed |
| EP-1922313-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | Laboratorios Almirall, S.A. (ES) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007017096-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| WO-2005054169-A1 | PREPARATION METHOD OF 2-PHENYLACETOPHENONE DERIVATIVES | HANBUL COSMETIC CO., LTD. (KR) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166566-A1 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES | ADRB2, ADRA2C, ADRA2A | SLC5A1 465/4885SLC5A2 174/4885HPGD 1192/4885 |
| US-20250084049-A1 | POLYCATIONIC SALTS OF PHENOLIC COMPOUNDS AND USES THEREOF | PGC, SLC5A6, PUF60 | SLC5A1 207/4885SLC5A2 70/4885HPGD 1526/4885 |
| US-20090042891-A1 | Pyrazine Derivatives Useful as Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA3 | SLC5A1 1176/4885SLC5A2 751/4885HPGD 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.